Pharmacists See Challenges, Opportunities In Behind-The-Counter Class
This article was originally published in The Tan Sheet
Executive Summary
Pharmacy trade groups welcome the possibility of a behind-the-counter class of drugs, but a pharmacy professor and former FDA Nonprescription Drugs Advisory Committee chairman cautions a third class could create more demand than pharmacists are able to manage
You may also be interested in...
“Behind-The-Counter” Drug Switches Must Tackle Restrictions On Use For Generics
Commissioner Hamburg says FDA asked for input on a “new paradigm” for nonprescription drug approvals in part because pharmaceutical firms have concerns about whether potential access restrictions imposed on an innovating switch would also apply to generic versions that eventually reach the market.
“Behind-The-Counter” Drug Switches Must Tackle Restrictions On Use For Generics
Commissioner Hamburg says FDA asked for input on a “new paradigm” for nonprescription drug approvals in part because pharmaceutical firms have concerns about whether potential access restrictions imposed on an innovating switch would also apply to generic versions that eventually reach the market.
FDA To Tackle Critical Generics Issue In Switch Paradigm Debate
Commissioner Hamburg says FDA asked for input on a “new paradigm” for nonprescription drug approvals in part because pharmaceutical firms have concerns about whether potential access restrictions imposed on an innovating switch would also apply to generic versions that eventually reach the market.